1 active not recruiting, 1 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow InnoCare Pharma Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL Orelabrutinib, Zuberitamab, Cyclophosphamide - Marginal Zone Lymphoma(MZL) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 65 | 2025-10-01 | 2026-04-02 |
| Evaluating Different Doses of Orelabrutinib in MCL Orelabrutinib High dose, Orelabrutinib Low dose - Mantle Cell Lymphoma | Phase 2 | Completed | InnoCare Pharma Inc. | 40 | 2023-08-18 | 2026-06-11 |
Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1)
orelabrutinib (2) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Vincristine (1)
China (2)